Evercore Initiates Coverage on Hemab Therapeutics (NASDAQ:COAG)

Equities research analysts at Evercore began coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a research report issued on Tuesday. The brokerage set an “outperform” rating and a $50.00 price target on the stock. Evercore’s price target suggests a potential upside of 93.12% from the stock’s current price.

Several other analysts also recently weighed in on the company. Jefferies Financial Group began coverage on Hemab Therapeutics in a research note on Tuesday. They set a “buy” rating and a $39.00 target price on the stock. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Wedbush began coverage on Hemab Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $42.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on Hemab Therapeutics in a research note on Tuesday. They set a “buy” rating and a $36.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $41.75.

Hemab Therapeutics Price Performance

NASDAQ:COAG opened at $25.89 on Tuesday. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. acquired 3,802 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were bought at an average price of $24.97 per share, with a total value of $94,935.94. Following the purchase, the insider owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. This represents a 0.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders acquired 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.